{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:50:40Z","timestamp":1740138640164,"version":"3.37.3"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ijid.2024.107237","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T07:14:39Z","timestamp":1726125279000},"page":"107237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety, reactogenicity, and immunogenicity of ZR-202-CoV and ZR-202a-CoV recombinant vaccines compared with Comirnaty\u24c7: A randomized, observer-blind, controlled, phase 1 study"],"prefix":"10.1016","volume":"148","author":[{"given":"Samba O.","family":"Sow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6476-3934","authenticated-orcid":false,"given":"Milagritos D.","family":"Tapia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadima C.","family":"Haidara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatoumata","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1250-608X","authenticated-orcid":false,"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bangwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Grappi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2173-7269","authenticated-orcid":false,"given":"Martina","family":"Monti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3652-5082","authenticated-orcid":false,"given":"Simonetta","family":"Viviani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0474-6256","authenticated-orcid":false,"given":"Min","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenliang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2024.107237_bib0001","unstructured":"WHO. Coronavirus (COVID-19) Dashboard. Accessed September 3, 2024. https:\/\/covid19.who.int\/."},{"key":"10.1016\/j.ijid.2024.107237_bib0002","unstructured":"COVID-19 Market Dashboard. Accessed September 3, 2024. https:\/\/www.unicef.org\/supply\/covid-19-market-dashboard."},{"key":"10.1016\/j.ijid.2024.107237_bib0003","unstructured":"Coronavirus pandemic (COVID-19). Accessed September 3, 2024. https:\/\/ourworldindata.org\/coronavirus."},{"key":"10.1016\/j.ijid.2024.107237_bib0004","unstructured":"Mali population. Accessed September 3, 2024. https:\/\/www.worldometers.info\/world-population\/mali-population\/."},{"key":"10.1016\/j.ijid.2024.107237_bib0005","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41541-022-00571-0","article-title":"A potent, broadly protective vaccine against SARS-CoV-2 variants of concern","volume":"7","author":"Wang","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ijid.2024.107237_bib0006","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1016\/j.vaccine.2021.10.066","article-title":"Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum\/CpG adjuvants","volume":"39","author":"Liu","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2024.107237_bib0007","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2262635","article-title":"Safety, tolerability, and immunogenicity of a CpG\/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial","volume":"19","author":"Feng","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijid.2024.107237_bib0008","unstructured":"COVID-19 Vaccines. Accessed September 3, 2024. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines"},{"key":"10.1016\/j.ijid.2024.107237_bib0009","doi-asserted-by":"crossref","first-page":"57","DOI":"10.18773\/austprescr.2021.008","article-title":"BNT162b2 vaccine for prevention of COVID-19","volume":"44","year":"2021","journal-title":"Aust Prescr"},{"key":"10.1016\/j.ijid.2024.107237_bib0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 vaccine: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ijid.2024.107237_bib0011","unstructured":"Reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2. Accessed September 3, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-regulatory-requirements-vaccines-intended-provide-protection-against-variant-strains-sars-cov-2_en.pdf."},{"key":"10.1016\/j.ijid.2024.107237_bib0012","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2024.107237_bib0013","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jinf.2022.06.014","article-title":"Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: a randomized trial","volume":"85","author":"Niyomnaitham","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.ijid.2024.107237_bib0014","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.7326\/M22-1300","article-title":"Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"175","author":"Follmann","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijid.2024.107237_bib0015","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine","volume":"386","author":"Moreira","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2024.107237_bib0016","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2024.107237_bib0017","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41421-023-00518-2","article-title":"Long-term and effective neutralization against omicron sublineages elicited by four platform COVID-19 vaccines as a booster dose","volume":"9","author":"Zhang","year":"2023","journal-title":"Cell Discov"},{"key":"10.1016\/j.ijid.2024.107237_bib0018","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41591-021-01325-6","article-title":"Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2","volume":"27","author":"Ebinger","year":"2021","journal-title":"Nat Med"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971224003084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971224003084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T21:28:55Z","timestamp":1729718935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971224003084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":18,"alternative-id":["S1201971224003084"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2024.107237","relation":{},"ISSN":["1201-9712"],"issn-type":[{"type":"print","value":"1201-9712"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, reactogenicity, and immunogenicity of ZR-202-CoV and ZR-202a-CoV recombinant vaccines compared with Comirnaty\u24c7: A randomized, observer-blind, controlled, phase 1 study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2024.107237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"107237"}}